Logo image of CHR-DB-B.CA

CHORUS AVIATION INC (CHR-DB-B.CA) Stock Fundamental Analysis

TSX:CHR-DB-B - Toronto Stock Exchange - CA17040TAE25 - Currency: CAD

100.3  +0.09 (+0.09%)

Fundamental Rating

4

Taking everything into account, CHR-DB-B scores 4 out of 10 in our fundamental rating. CHR-DB-B was compared to 8 industry peers in the Passenger Airlines industry. CHR-DB-B has only an average score on both its financial health and profitability. CHR-DB-B does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

CHR-DB-B had positive earnings in the past year.
In the past year CHR-DB-B had a positive cash flow from operations.
Of the past 5 years CHR-DB-B 4 years were profitable.
In the past 5 years CHR-DB-B always reported a positive cash flow from operatings.
CHR-DB-B.CA Yearly Net Income VS EBIT VS OCF VS FCFCHR-DB-B.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M -400M -600M

1.2 Ratios

CHR-DB-B has a Return On Assets of -4.13%. This is in the lower half of the industry: CHR-DB-B underperforms 60.00% of its industry peers.
CHR-DB-B has a Return On Equity of -25.78%. This is in the lower half of the industry: CHR-DB-B underperforms 60.00% of its industry peers.
The Return On Invested Capital of CHR-DB-B (6.92%) is better than 90.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CHR-DB-B is in line with the industry average of 6.19%.
The last Return On Invested Capital (6.92%) for CHR-DB-B is above the 3 year average (4.44%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -4.13%
ROE -25.78%
ROIC 6.92%
ROA(3y)0.57%
ROA(5y)1.49%
ROE(3y)1.59%
ROE(5y)6.65%
ROIC(3y)4.44%
ROIC(5y)4.57%
CHR-DB-B.CA Yearly ROA, ROE, ROICCHR-DB-B.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60 80

1.3 Margins

CHR-DB-B's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 9.52%, CHR-DB-B is in line with its industry, outperforming 50.00% of the companies in the same industry.
CHR-DB-B's Operating Margin has been stable in the last couple of years.
CHR-DB-B has a Gross Margin of 66.55%. This is amongst the best in the industry. CHR-DB-B outperforms 90.00% of its industry peers.
CHR-DB-B's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 9.52%
PM (TTM) N/A
GM 66.55%
OM growth 3Y-6.77%
OM growth 5Y-0.51%
PM growth 3Y-3.58%
PM growth 5Y-4.67%
GM growth 3Y-3.81%
GM growth 5Y0.91%
CHR-DB-B.CA Yearly Profit, Operating, Gross MarginsCHR-DB-B.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60 80

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CHR-DB-B is destroying value.
The number of shares outstanding for CHR-DB-B has been reduced compared to 1 year ago.
CHR-DB-B has less shares outstanding than it did 5 years ago.
CHR-DB-B has a better debt/assets ratio than last year.
CHR-DB-B.CA Yearly Shares OutstandingCHR-DB-B.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
CHR-DB-B.CA Yearly Total Debt VS Total AssetsCHR-DB-B.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B 4B

2.2 Solvency

Based on the Altman-Z score of 0.88, we must say that CHR-DB-B is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CHR-DB-B (0.88) is comparable to the rest of the industry.
The Debt to FCF ratio of CHR-DB-B is 3.29, which is a good value as it means it would take CHR-DB-B, 3.29 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 3.29, CHR-DB-B belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
CHR-DB-B has a Debt/Equity ratio of 0.89. This is a neutral value indicating CHR-DB-B is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.89, CHR-DB-B is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF 3.29
Altman-Z 0.88
ROIC/WACC0.88
WACC7.84%
CHR-DB-B.CA Yearly LT Debt VS Equity VS FCFCHR-DB-B.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M -500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 1.13 indicates that CHR-DB-B should not have too much problems paying its short term obligations.
With a Current ratio value of 1.13, CHR-DB-B perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
CHR-DB-B has a Quick Ratio of 1.07. This is a normal value and indicates that CHR-DB-B is financially healthy and should not expect problems in meeting its short term obligations.
CHR-DB-B has a Quick ratio of 1.07. This is comparable to the rest of the industry: CHR-DB-B outperforms 50.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 1.07
CHR-DB-B.CA Yearly Current Assets VS Current LiabilitesCHR-DB-B.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CHR-DB-B have decreased strongly by -49.86% in the last year.
CHR-DB-B shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -19.73% yearly.
The Revenue for CHR-DB-B has decreased by -13.31% in the past year. This is quite bad
Measured over the past years, CHR-DB-B shows a small growth in Revenue. The Revenue has been growing by 4.43% on average per year.
EPS 1Y (TTM)-49.86%
EPS 3Y-9.89%
EPS 5Y-19.73%
EPS Q2Q%0%
Revenue 1Y (TTM)-13.31%
Revenue growth 3Y21.01%
Revenue growth 5Y4.43%
Sales Q2Q%-23.59%

3.2 Future

Based on estimates for the next years, CHR-DB-B will show a very strong growth in Earnings Per Share. The EPS will grow by 76.49% on average per year.
Based on estimates for the next years, CHR-DB-B will show a decrease in Revenue. The Revenue will decrease by -5.76% on average per year.
EPS Next Y286.33%
EPS Next 2Y167.79%
EPS Next 3Y76.49%
EPS Next 5YN/A
Revenue Next Year-14.57%
Revenue Next 2Y-8.18%
Revenue Next 3Y-5.76%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CHR-DB-B.CA Yearly Revenue VS EstimatesCHR-DB-B.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B
CHR-DB-B.CA Yearly EPS VS EstimatesCHR-DB-B.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2 4 6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

CHR-DB-B is valuated quite expensively with a Price/Earnings ratio of 557.22.
60.00% of the companies in the same industry are cheaper than CHR-DB-B, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of CHR-DB-B to the average of the S&P500 Index (29.62), we can say CHR-DB-B is valued expensively.
A Price/Forward Earnings ratio of 46.62 indicates a quite expensive valuation of CHR-DB-B.
CHR-DB-B's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. CHR-DB-B is more expensive than 60.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, CHR-DB-B is valued quite expensively.
Industry RankSector Rank
PE 557.22
Fwd PE 46.62
CHR-DB-B.CA Price Earnings VS Forward Price EarningsCHR-DB-B.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300 400 500

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CHR-DB-B is valued a bit more expensive than 60.00% of the companies in the same industry.
CHR-DB-B's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CHR-DB-B is cheaper than 80.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.43
EV/EBITDA 11.99
CHR-DB-B.CA Per share dataCHR-DB-B.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CHR-DB-B's earnings are expected to grow with 76.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.95
PEG (5Y)N/A
EPS Next 2Y167.79%
EPS Next 3Y76.49%

More info and screens

0

5. Dividend

5.1 Amount

CHR-DB-B does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHORUS AVIATION INC

TSX:CHR-DB-B (2/18/2025, 7:00:00 PM)

100.3

+0.09 (+0.09%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryPassenger Airlines
Earnings (Last)02-19 2025-02-19/amc
Earnings (Next)05-05 2025-05-05/amc
Inst Owners1.95%
Inst Owner ChangeN/A
Ins Owners1.18%
Ins Owner ChangeN/A
Market Cap2.70B
Analysts76.36
Price Target135.21 (34.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend1.25
Dividend Growth(5Y)25.28%
DP-24.91%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)63.88%
Min EPS beat(2)-80.2%
Max EPS beat(2)207.96%
EPS beat(4)2
Avg EPS beat(4)23.18%
Min EPS beat(4)-80.2%
Max EPS beat(4)207.96%
EPS beat(8)2
Avg EPS beat(8)1.42%
EPS beat(12)4
Avg EPS beat(12)0.54%
EPS beat(16)6
Avg EPS beat(16)-3.74%
Revenue beat(2)0
Avg Revenue beat(2)-9.12%
Min Revenue beat(2)-10.27%
Max Revenue beat(2)-7.96%
Revenue beat(4)2
Avg Revenue beat(4)-3.07%
Min Revenue beat(4)-10.27%
Max Revenue beat(4)5.86%
Revenue beat(8)5
Avg Revenue beat(8)-0.16%
Revenue beat(12)7
Avg Revenue beat(12)2.1%
Revenue beat(16)9
Avg Revenue beat(16)5.94%
PT rev (1m)0.98%
PT rev (3m)7.4%
EPS NQ rev (1m)17.14%
EPS NQ rev (3m)-2.39%
EPS NY rev (1m)595.46%
EPS NY rev (3m)912.53%
Revenue NQ rev (1m)-0.62%
Revenue NQ rev (3m)-11.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.24%
Valuation
Industry RankSector Rank
PE 557.22
Fwd PE 46.62
P/S 1.83
P/FCF 13.43
P/OCF 10.62
P/B 4.85
P/tB 4.93
EV/EBITDA 11.99
EPS(TTM)0.18
EY0.18%
EPS(NY)2.15
Fwd EY2.14%
FCF(TTM)7.47
FCFY7.44%
OCF(TTM)9.45
OCFY9.42%
SpS54.69
BVpS20.66
TBVpS20.33
PEG (NY)1.95
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.13%
ROE -25.78%
ROCE 10.13%
ROIC 6.92%
ROICexc 7.04%
ROICexgc 7.09%
OM 9.52%
PM (TTM) N/A
GM 66.55%
FCFM 13.65%
ROA(3y)0.57%
ROA(5y)1.49%
ROE(3y)1.59%
ROE(5y)6.65%
ROIC(3y)4.44%
ROIC(5y)4.57%
ROICexc(3y)4.59%
ROICexc(5y)4.75%
ROICexgc(3y)4.62%
ROICexgc(5y)4.78%
ROCE(3y)6.5%
ROCE(5y)6.69%
ROICexcg growth 3Y10.79%
ROICexcg growth 5Y-5.04%
ROICexc growth 3Y10.61%
ROICexc growth 5Y-5.1%
OM growth 3Y-6.77%
OM growth 5Y-0.51%
PM growth 3Y-3.58%
PM growth 5Y-4.67%
GM growth 3Y-3.81%
GM growth 5Y0.91%
F-Score5
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF 3.29
Debt/EBITDA 1.78
Cap/Depr 38.58%
Cap/Sales 3.62%
Interest Coverage 1.61
Cash Conversion 91.39%
Profit Quality N/A
Current Ratio 1.13
Quick Ratio 1.07
Altman-Z 0.88
F-Score5
WACC7.84%
ROIC/WACC0.88
Cap/Depr(3y)28.67%
Cap/Depr(5y)181.33%
Cap/Sales(3y)4.59%
Cap/Sales(5y)24.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49.86%
EPS 3Y-9.89%
EPS 5Y-19.73%
EPS Q2Q%0%
EPS Next Y286.33%
EPS Next 2Y167.79%
EPS Next 3Y76.49%
EPS Next 5YN/A
Revenue 1Y (TTM)-13.31%
Revenue growth 3Y21.01%
Revenue growth 5Y4.43%
Sales Q2Q%-23.59%
Revenue Next Year-14.57%
Revenue Next 2Y-8.18%
Revenue Next 3Y-5.76%
Revenue Next 5YN/A
EBIT growth 1Y-52.82%
EBIT growth 3Y12.82%
EBIT growth 5Y3.9%
EBIT Next Year2.27%
EBIT Next 3Y-7.57%
EBIT Next 5YN/A
FCF growth 1Y4.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.66%
OCF growth 3Y24.15%
OCF growth 5Y4.61%